Summary:
The study will investigate the efficacy, safety, tolerability and PK of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
Qualified Participants Must:
• Be 18 years of age or older (Adult, Senior)
•
Be a male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes >1 year
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.